Advanced search
Publication Cover
Cancer Biology & Therapy Volume 16, 2015 - Issue 2
Submit an article Journal homepage
1,498
Views
10
CrossRef citations to date
0
Altmetric
Bedside to Bench Reports

Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review

Bin ZhangDepartment of Oncology; The First Affiliated Hospital of Dalian Medical University; Dalian, PR China;Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University; Jinan, PR China
,
Xia ZhangDepartment of Oncology; Shandong Cancer Hospital and Institute; Jinan, PR China
,
Tao ZhouDepartment of Oncology; The First Affiliated Hospital of Dalian Medical University; Dalian, PR China
&
Jiwei LiuDepartment of Oncology; The First Affiliated Hospital of Dalian Medical University; Dalian, PR ChinaCorrespondence[email protected]
Pages 215-218 | Received 16 Aug 2014, Accepted 02 Sep 2014, Published online: 10 Mar 2015

References

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 6l:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
  • Chen WQ, Zhang SW, Zeng HM, Zheng RS, Zou XN, Zhao P, Wu LY, Li GL, Hao J. Report of Cancer Incidence and Mortality in China, 2010. China Cancer 2014; 23:1-10.
  • Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, Greten TF, Raymond E, Roskams T, De Baere T, et al.. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943.
  • Reataza M, Imagawa DK. Advances in managing hepatocellular carcinoma. Front Med 2014; 8:175-189; PMID:24810646; http://dx.doi.org/10.1007/s11684-014-0332-4
  • Peck-Radosavljevic M. Drug therapy for advanced-stage liver cancer. Liver Cancer 2014; 3:125-131; PMID:24945003; http://dx.doi.org/10.1159/000343868
  • Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V, et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010; 15:285-292; PMID:20203173; http://dx.doi.org/10.1634/theoncologist.2009-0316
  • Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31:4067-4075; PMID:24081937; http://dx.doi.org/10.1200/JCO.2012.45.8372
  • Llovet JM1, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20:2072-2079; PMID:24589894; http://dx.doi.org/10.1158/1078-0432.CCR-13-0547
  • Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31:3517-3524; PMID:23980084; http://dx.doi.org/10.1200/JCO.2012.48.4410
  • Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 31:3509-3516; PMID:23980090; http://dx.doi.org/10.1200/JCO.2012.47.3009
  • Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 2012; 118:2424-2430; PMID:21953248; http://dx.doi.org/10.1002/cncr.26556
  • Govindarajan R, Siegel E, Makhoul I, Williamson S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol 2013; l 36:254-257; http://dx.doi.org/10.1097/COC.0b013e318248d83f
  • Chen L1, Liu H, Liu J, Zhu Y, Xu L, He H, Zhang H, Wang S, Wu Q, Liu W, et al. Klotho endows hepatoma cells with resistance to anoikis via VEGFR2/PAK1 activation in hepatocellular carcinoma. PLoS One 2013; 8:e58413; PMID:23516476; http://dx.doi.org/10.1371/journal.pone.0058413
  • Bruix J1, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 2013; 49:3412-3419; PMID:23809766; http://dx.doi.org/10.1016/j.ejca.2013.05.028
  • Scagliotti GV1, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013; 39:793-801; PMID:23453860; http://dx.doi.org/10.1016/j.ctrv.2013.02.001
  • Xiang Q, Chen W, Ren M, Wang J, Zhang H, Deng DY, Zhang L, Shang C, Chen Y. Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET. Clin Cancer Res 2014; 20:2959-2970; PMID:24700742; http://dx.doi.org/10.1158/1078-0432.CCR-13-2620
  • Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebocontrolled phase 2 study. Lancet Oncol 2013; 14:55-63; PMID:23182627; http://dx.doi.org/10.1016/S1470-2045(12)70490-4

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.